1. Scrip

Tricida's Future In Doubt After Renal Outcomes Failure In CKD With Metabolic Acidosis

 
• By Jessica Merrill

The company's hopes to bring veverimer to market to slow chronic kidney disease progression in patients with metabolic acidosis appear to be dashed.

end of the road
Tricida may have hit the end of the road with veverimer • Source: Shutterstock

Tricida, Inc.'s ambitions to bring the first drug to market to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis appear have been derailed by a failure in a large renal outcomes trial. The company announced on 24 October that the VALOR-CKD renal outcomes study testing veverimer failed to meet the primary endpoint, apparently due to a high placebo response rate.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

UK Promises To ‘Turbo-Charge’ Clinical Trials As Tariff Threat Remains

 
• By Andrew McConaghie

Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.